Purpose: Throughout the years, the palliative treatment of bone metastases using bone seeking radiotracers has been part of the therapeutic resources used in oncology, but the choice of which bone seeking agent to use is not consensual across sites and limited data is available comparing the characteristics of each radioisotope.
INTRODUCTION
Cancer is a major public health concern, and it is associated with significant morbidity and mortality.
In 2012, approximately 14 million new cases were diagnosed, and 8 million cancer-related deaths occurred.
Prostate cancer is the second most common cancer in men worldwide.
1 A large percentage of patients with prostate cancer (65-75%) develop bone metastasis [2] [3] [4] , which often leads to severe pain, hypercalcemia, lack of mobility and depression that adversely affect these patients' life quality. 5 There are several therapeutic approaches targeting bone metastases and its associated effects, including the use of analgesics, external beam radiotherapy and radionuclide systemic therapy. The latter, systemic palliative targeted-therapy with suitable radiotracers, has emerged as a particularly appealing and efficient treatment modality for patients with multiple skeletal metastases. 3, [6] [7] [8] Over the years, efforts were made to identify radionuclides with improved physical properties for use in palliative care of metastatic bone pain, as well as to develop better bone seeking agents to be used for radiolabelling with promising radionuclides. A major challenge associated with the palliative treatment of bone pain using selective radiotracers is to deliver an adequate dose of ionizing radiation to the bone lesion, while minimizing the dose to healthy bone sites and adjacent tissues. The radionuclide emitted particles should have an energy and tissue penetration range compatible with the volume of the lesion to be irradiated 2, 9 , given that both the energy and the penetrating range of a radionuclide emitted particle significantly contribute to the therapy efficacy. 10 Therefore, studying the effects of particulate radiation at the cellular level is of interest to determine the suitability of a given radionuclide for target-tumor radiotherapy. There are essentially three main types of radioactive particles that are of interest for target-tumor radiotherapy: beta minus (β -) particles, alpha (α) particles and Auger electrons. The β -particles present an average range of few millimeters, which may result in neighboring cells irradiation due to crossfire. By contrast, α particles have a typical penetration range of less than 100 µm. 11 Auger electrons are low energy electrons (typical energies around 20-100 KeV) and have short penetration ranges of few nanometers to micrometers. Owing to their short penetration range, systemic target-tumor radiotherapy with Auger electrons often yields lower toxicity to the bone marrow in comparison to β -particles. 12 In addition to the physical properties of different radionuclides for target-tumor therapy, other characteristics should be taken into consideration while searching for the ideal radiotracer for palliative treatment of bone metastases. For example, the radionuclide production costs and feasibility should be determined, and consideration should be given on whether its properties are amenable for radiochemistry procedures. 8 It is also important that the radionuclide to be used for palliative treatment of bone metastases 4 allows for in vivo imaging, in order to assist with the determination of the suitable therapeutic dose to be used and to facilitate treatment monitoring. 6, 13 In recent years, several reports have been published describing the use of multiple radionuclides in the context to palliative treatment of bone metastases. Radioisotopes investigated for this application included:
Phosphorus 2, 5, 6, [9] [10] [11] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] . The main physical characteristics of these radionuclides are presented in Table 1 . Legend: T 1/2 (days) -radioisotope half-life in days; E (MeV) (%) -particle energy and respective decay abundance shown in parentheses; E γ (KeV) (%) -gamma ray energy and respective abundance in total energy emission shown in parentheses; Tissue penetration range (mm) -maximum tissue penetration shown in millimeters. Despite the increasing availability of radionuclides for palliative treatment of bone metastases 26, 35 , the choice of which therapeutic agent to use is not consensual across sites and no standardization or guideline exists to assist with this choice. This may be due to the limited data available comparing the advantages and disadvantages of each radioisotope, as well as assessing all radioisotopes in the same test conditions.
Computational simulation is a simple and practical method to study and to compare a variety of radioisotopes for different medical applications, including the palliative treatment of bone metastases, under the same research conditions. This study aims to use computational methods to evaluate and compare different radioisotopes currently in use or under research for the palliative treatment of bone metastases. In particular, the data reported here will focus on the bone metastases from the prostate carcinoma, given this is one of the most common types of cancer in men worldwide and the majority of these patients develop bone metastases.
II. METHODS
Three different computational simulators were used to investigate the therapeutic potential of the 6 following radioisotopes: 3 
II.A. Fast Monte Carlo damage formation simulator
The Monte Carlo damage simulation (MCDS) algorithm can be used to predict the types of 
II.B. Fast Monte Carlo excision repair simulator
The Monte Carlo excision repair (MCER) algorithm can be used to calculate the formation and repair of DNA damages and to predict repair outcomes such as correct repair, repair with a mutation and conversion into a DSB. 44 The MCER algorithm starts by using the MCDS algorithm to generate a random number of damage configurations expected within the DNA of one cell. Subsequently, the MCDS-generated damage configurations are superimposed over a predetermined nucleotide sequence or a random nucleotide sequence.
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Then, the MCER model is used to simulate the repair, misrepair and aborted excision repair of damage within the entire genome or within a specific region of the DNA. The lesions forming a cluster are removed sequentially through repeated rounds of excision repair.
The majority of DNA oxidative damage, including modified apurinic/apyrimidinic converted into strand breaks, requires repair by base excision repair (BER). Two different types of BER processes have been observed in eukaryotic and prokaryotic cells: (1) e xcision and replacement of a single nucleotide, known as short-patch BER (SP-BER), which occurs in most cases; and (2) 45 A detailed description of the MCER algorithm, as well as additional discussions on the validity and limitations of the model can be found in references 40 and 44 .
II.C. Virtual cell radiobiology simulator
The radiation-induced damage can be lethal or can be slowly repaired via enzymatic repair and misrepair, which then determines the fate of the irradiated cell. The cell cycle kinetics can influence and/or be influenced by the kinetics of damage processing; and damages to the DNA are often a trigger for apoptosis, although cell membrane damages can also induce apoptosis. 44, 46 Radiobiological models have been developed to describe the dose-response association, the process of damage production and the key repair mechanisms. These models often correlate the dose rate with the cell response to irradiation. Some of the existing models include the repair-misrepair (RMR) model, lethal-potentially lethal (LPL) model and twolesion kinetics (TLK). 46 The main disadvantage of the LPL model is its inability to correlate the biochemical processes of DSB with the cell death. The RMR and linear quadratic models also share this limitation.
Conversely, the TLK model carries out an improved correlation between the biochemical processes of DSB and the cell death by subdividing DSB into simple or complex DSBs. This subdivision is important since simple and complex DSBs have different repair characteristics. 47 Therefore, all simulations carried out here using the Virtual Cell (VC) radiobiology simulator were performed using the TLK model. Further 8 details on this computational simulator can be found at: http://faculty.washington.edu/trawets/vc.
II.D. Simulated parameters
For each investigated radioisotope, only the most abundantly emitted radioactive particles were evaluated using the MCDS and MCER simulators. 
II.E. Statistical analysis
The MCDS results are expressed as a percentage of damage. The MCER results are expressed as a probability of repair or number of cell cycles. The VC values are expressed as survival fraction or the number of surviving cells. The statistical significance was determined using ANOVA (p < 0.01). 
III. RESULTS

III.A. MCDS and MCER results
Figs
III.B. VC simulator
The cell survival fraction results obtained after irradiation with different radionuclides and particles are shown in Fig. 5 Additionally, statistically significant differences were observed among the different irradiating agents (p < 0.0001 and p = 0.0053 ANOVA, with and without 223 Ra data, respectively). 
IV. DISCUSSION AND CONCLUSION
Here we report the use of different computational methods to evaluate multiple radioisotopes for the The MCDS results showed that the percentage of SSB and DSB after irradiation were highest for 223 Ra α particles, followed by 177 Lu β -particles. The same trend was observed for a percentage of complex SSB and DSB. Conversely, the probability of correct repair was low for these irradiating agents and the number of repair cycles was high for all the repair processes studied, regardless of the repair route (MCER results). A higher number of repair cell cycles has been correlated with prolonged repair times 45, 49 , which correlates with increased percentage of complex damages. Previous studies have demonstrated that the complex damage repair by excision can lead to an increased number of DSBs. 45, 50 It is well known that DNA DSBs are frequently associated with apoptosis induction. 41 The damage induced by 223 Ra α particles and 177 Lu β -particles seem to have hampered the successful repair of the DNA by BER or NER, presenting a high probability for DSB formation and low probability for correct repair.
Furthermore, the high number of DNA DSBs induced by the 223 Ra α particles and 177 Lu β -particles together with their high DNA SSB conversion to DSB may translate an increased probability of apoptosis induction for these three radioisotopes compared with the other investigated agents. In fact, data from the VC simulator estimated a low survival fraction for 223 Ra α particles and 177 Lu β -particles, suggesting these irradiating agents would be more promising in the killing of metastatic cells than the other investigated irradiating agents. Furthermore, the VC simulator estimated a low survival fraction for cells irradiated with 170 Tm β -particles. Interestingly, the total number of DSB induced by DNA irradiation with 170 Tm β -particles was in the low range, but the percentage of complex DSB was ranked together with 177 Lu β -particles, which supports for the importance of modelling the fraction of complex DSB when determining the radiation induced cell damages using radiobiological models. Data also showed that a larger number of metastatic cells survived irradiation when compared with normal prostatic cells, in particular, when all cells were actively dividing. This observation highlights the influence of cell proliferation rate on cell response to irradiation, where a faster cell cycle time means the cells were less radiosensitive. Due to its shorter doubling time (54 days versus 500 days for metastatic and normal cells, respectively), metastatic prostate cells were able to compensate radiation-induced damage by rapid cell duplication.
223 Ra α particle emission is an appealing strategy for the treatment of bone micrometastases, owing to the short tissue range penetration associated with these radioactive particles that can allow for a more circumscribed irradiation surface. Furthermore, typically α emitters induce less hematologic toxicity for a given bone surface dose than β -emitters. 6, 11, 16 The high linear energy transfer of α particles has been associated with greater biological effectiveness than β -particles. 6, 11, 16 Our findings using computational simulation indicated that 223 Ra α particles induced significantly more DSBs and were more effective in inducing cell death than all the other particles. To date, the 223 Ra-dicloride has been the only radiotracer identified for treatment of palliative bone metastasis with shown ability to increase patients' life-expectancy.
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Within the β -particle emitters investigated here, the 177 Lu has the lowest tissue penetration range (1.8 mm). A common concern associated with the use of β -particle emitters is related to its large tissue penetration range of several millimeters, which can result in energy deposition in neighboring, non-targeted cells, a phenomenon known as "crossfire" that may lead to bystander effects. With α particle emitters, due to their short tissue penetration range, the "crossfire" effect is not such a concern, but may require targeting virtually every cell within large size tumors and does not take advantage of the positive bystander effects. 39 
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The short tissue penetration range of 177 Lu β -particles is placed in the lowest end of the β -particle emitter's tissue penetration range, minimizing the negative "crossfire" effects often associated with β -particle emitters;
and it is higher than typical α particles allowing us to take advantage of the positive bystander effects that are not attainable with conventional α particles emitters. In addition, 177 Lu low β -particle energy and intermediate physical half-life of 6.73 days allow for a constant dose rate in the target lesion sites. 25 Here we found that 177 Lu β -particles induced the maximum number of DSB among all β -emitters studied radionuclides and was part of the top three most effective radionuclides to induce cell death. The clinical outcomes of the palliative treatment of bone metastases using radiotracers can vary with the used radionuclide and radiotracer (see, Supplementary Table 1) . Notwithstanding, previously published data has shown that the 223 Ra α particles have an increased anti-tumor effect when compared with β -particles. 6, 16, 28 This might explain recent data demonstrating that 223 Ra was the first agent in its class to show an overall survival advantage in patients with bone metastases from prostate carcinomas. 35 In line with these observations, our in silico analysis showed a superiority of 223 Ra α particles compared with the modelled β -particles.
Computational methods allow for rapid and easy data collection. Nonetheless, some limitations have been pointed out, including modeling and evaluation based on current knowledge, which works as a mechanistic process. Furthermore, the computational algorithms used in this study only model simple repair processes and exclude DSBs repair processes, such as homologous repair and non-homologous end joining (NHEJ) repair processes. Moreover, the used algorithms assume an optimal scenario of ionizing energy deposition directly into the DNA, scenario that often is challenging to achieve in vitro and in vivo due to inefficient radiotracer biodistribution processes. Notwithstanding, thus far, results from in silico testing using the VC simulator have been compared with data from a total of 23 in vitro datasets obtained using different cell types and exposure conditions. Results from that in silico versus in vitro comparison demonstrated that the simulated data obtained using the VC algorithm compared favorably with real-life measured data. Results from comparative tests against 23 published radiobiological datasets can be found at http://faculty.washington.edu/trawets/archive/index.html. Therefore, although validation of the used simulators has been carried out in selected irradiation scenarios and specific cellular populations 40, 47, 50, 52 , indicating these methods can be useful as a first-line approach to large data sets to help planning subsequent in vitro and in vivo studies, the data presented here requires further validation by means of in vitro and in vivo studies to fully establish the therapeutic potential of the investigated radioisotopes in the context of palliative treatment of bone metastases. In particular, because the clinical outcome of a given therapeutic depends not only on the cellular response, but also on, for example, the individual patient differences in clinical conditions, patient preparedness, life expectancy, age and the existence of secondary tumors. Furthermore, aspects such as radiotracer biodistrubition, elimination and concentration in the biological target tissue in vivo would also impact therapeutic response.
In conclusion, this study compared different irradiating agents using the same exposure conditions and controllable cell populations to clarify the quality of these radioisotopes for palliative treatment of bone metastases, specifically in the context of prostate cancer. Collected data allowed the ranking of eleven different radioisotopes in terms of ability to induce DNA damage and probability of damage repair. 
